Abstract 1629P
Background
The management of pancreatic adenocarcinoma continues to be challenging. Surgical resection is the only modality for a cure, with an overall survival rate of 10–20% at 5 years. However, only 20% of the patients are surgical candidates because of locally advanced disease or systemic stage at presentation.
Methods
A phase II clinical trial was carried out on 50 patients with previously untreated locally advanced, surgically unresectable pancreatic adenocarcinoma. Patients had ECOG PS 0 or 1 and adequate hematologic, renal, and hepatic function. They arranged to receive 3 cycles of modified FOLFIRINOX prior to CCRT, with losartan taken orally every day followed by chemoradiotherapy.
Results
Response after completion CCRT was assessed. 6% of patients achieved complete response. 38% of the patients had a partial response, while twenty-four patients (48%) had stable disease and 8% had progressive disease. Of the 50 patients, thirteen (26%) underwent surgery, with R0 resection achieved in 6 of 13 patients. Median follow-up period was 20.25 months (range, 6.0-34.5). The median PFS was 12 months (95% CI, 9.647 – 14.353), while Median OS was 21 months (95% CI, (10.200–31.800). The patients who underwent resection had longer survival 24 months (95% CI, (16.363 – 27.637) compared to those who did not undergo resection; mean OS was 14 months (95% CI, (9.205 – 18.795)). (P=0.271). The patients who achieved CR after modified Folforinox-losartan had a longer median OS of 33 months (95% CI, 19.918 – 46.082) compared to patients who had PR and SD, each had median OS of 13 months (95% CI, 6.768 – 19.232), (11.718 – 14.282) respectively (P=0.040*). The patients who achieved CR after CCRT had longer OS (NR) compared to those who had PR, SD and PD. median OS was 24, 14 and 8 months, respectively (95% CI, 6.761 – 41.239), (11.022 – 16.978), and (95% CI, 4.080 – 11.920) (P=<0.001*). The patients who achieved CR after CCRT had longer PFS (NR) compared to those who had PR, SD and PD. Median PFS was 24 (95% CI, 13.191 – 34.809), 10(95% CI, 4.973 – 15.027) and 5 (95% CI,4.823-5.124) months, respectively (P=<0.001*).
Conclusions
Induction chemotherapy with modified-FOLFIRINOX-losartan, followed by CCRT improved patient outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Menoufia University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1645P - STAT3, ACTA2, and SPARC stromal markers predict response to Gemcitabine/Cisplatin/Nab-paclitaxel (GCN) in patients with advanced pancreatic adenocarcinoma (apdac)
Presenter: Himil Mahadevia
Session: Poster session 22
1646P - Genomic and prognostic differences in patients with different KRAS mutations in pancreatic cancer
Presenter: Chunwei Xu
Session: Poster session 22
1647P - Cancer-associated endocrine cell: A novel component of tumor microenvironment in pancreatic cancer
Presenter: Yuan Chen
Session: Poster session 22
1648P - Association between circulating tumor cell count and thrombosis in pancreatic cancer
Presenter: Monica Benavente
Session: Poster session 22
1649P - Comprehensive genomic profiling contributes to the prognosis of patients with advanced pancreatic cancer
Presenter: Eiichiro So
Session: Poster session 22
1650P - Identification of potential targets in pancreatic adenocarcinoma: The KRAS Wild-Type subset
Presenter: Daniel Acosta Eyzaguirre
Session: Poster session 22
1651P - Comparison of surgical outcome and prognostic factors between pancreaticobiliary and intestinal types of periampullary adenocarcinoma following pancreaticoduodenectomy
Presenter: Saad Anwar
Session: Poster session 22
1652P - Interaction between enhanced cytokine signalling and ferroptosis defence fuels obesity-associated pancreatic ductal adenocarcinoma oncogenesis
Presenter: Rishat Ruzi
Session: Poster session 22
1653P - The activated thermogenesis of intra-pancreatic fat fuels the progression of pancreatic cancer
Presenter: Xi'n'peng Yin
Session: Poster session 22
1654P - Circulating tumor cells (CTCs) as prognostic factor for pancreatic cancer: Updated of a prospective study
Presenter: Natalia Gutierrez Alonso
Session: Poster session 22